lipid-a and Severe-Acute-Respiratory-Syndrome

A subunit vaccine, RBD-S, is under development to prevent severe acute respiratory syndrome (SARS) caused by SARS coronavirus (SARS-CoV), which is classified by the US NIH as a category C pathogen. This vaccine is comprised of a recombinant receptor-binding domain (RBD) of the SARS-CoV spike (S) protein and formulated on alum, together with a synthetic glucopyranosyl lipid A. The vaccine would induce neutralizing antibodies without causing Th2-type immunopathology. Vaccine development is being led by the nonprofit product development partnership; Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development in collaboration with two academic partners (the New York Blood Center and University of Texas Medical Branch); an industrial partner (Immune Design Corporation); and Walter Reed Army Institute of Research. A roadmap for the product development of the RBD-S SARS vaccine is outlined with a goal to manufacture the vaccine for clinical testing within the next 5 years.

Topics: Adjuvants, Immunologic; Aluminum Compounds; Animals; Antibodies, Neutralizing; Antibodies, Viral; Antigens, Viral; Clinical Trials as Topic; Humans; Lipid A; Membrane Glycoproteins; Phosphates; Protein Structure, Tertiary; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Spike Glycoprotein, Coronavirus; Vaccines, Subunit; Vaccines, Synthetic; Viral Envelope Proteins; Viral Vaccines